214487-46-4

MEN11467 produces a long lasting (>2-3 h) dose-dependent antagonism of bronchoconstriction induced by the selective tachykinin NK₁ receptor agonist, [Sar⁹, Met(O₂)¹¹]SP in anaesthetized guinea-pigs (ID₅₀s=29±5, 31±12 and 670±270 μg/kg, after intravenous, intranasal and intraduodenal administration, respectively), without affecting bronchoconstriction induced by methacholine. After oral administration MEN11467 produces a dose-dependent inhibition of plasma protein extravasation induced in guinea-pig bronchi by [Sar⁹, Met(O₂)¹¹] (ID₅₀= 6.7±2 mg/kg) or by antigen challenge in sensitized animals (ID₅₀=1.3 mg/kg). After i.v. administration MEN11467 weakly inhibits the GR 73632-induced foot tapping behaviour in gerbil (ED₅₀=2.96±2 mg/kg), indicating a poor ability to block central tachykinin NK₁ receptors^[1]. Treatment with MEN11467 (1 mmol/kg twice weekly for 2 weeks) results in a temporary growth arrest of the U373 MG xenograft that last for about 10 days until the last MEN11467 administration (TVI%=56). Thereafter, the tumor start to regrow. MEN11467 anti-tumor activity is partially reverted by the simultaneous administration of an equimolar dose of exogenous substance P (SP), suggesting the specificity of tachykinin NK1 receptor activation in glioma growth. Prolonged s.c. treatment with a higher MEN11467 dose (1.7 mmol/kg at five times a week for 6 weeks) completely inhibits the growth of U373 MG tumor for the entire length of the experiment, even following administration of a low exogenous SP dose. After 6 weeks, the tumor mass is not increased compared to the untreated control with TVI%=96%^[3].